Market Overview

UPDATE: J.P. Morgan Reiterates Overweight Rating, Lowers PT on Amarin Corporation

Share:
Related AMRN
UPDATE: What Amarin Would Need To Disclose To Ensure Non-Misleading Speech
First Amendment Decision a Win for Amarin and Physician Plaintiffs

In a report published Friday, J.P. Morgan & Co. reiterated its Overweight rating on Amarin Corporation plc (NASDAQ: AMRN), but lowered its price target from $20.00 to $18.00.

J.P. Morgan noted, “Maintain Overweight rating. Vascepa, Amarin's primary pipeline asset, is a purified fish oil product and represents a potential $1+ billion product opportunity, in our view. The product, which reduces triglycerides, has shown highly favorable data and is able to address both the very high triglyceride and the larger high triglyceride with mixed dyslipidemia markets. Following FDA approval for Vascepa in July 2012 and see significant strategic value for the asset should Amarin seek to partner the product or sell itself.”

Amarin Corporation plc closed on Thursday at $7.68.

Latest Ratings for AMRN

DateFirmActionFromTo
Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (AMRN)

Get Benzinga's Newsletters